Accretion Pharmaceuticals FY26: ₹9.67 Cr Profit, Minus ₹14.62 Cr From Operations

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Accretion Pharmaceuticals closed FY26 with sales of ₹89.63 crore, up from ₹57.38 crore a year earlier, and a net profit of ₹9.67 crore. On paper, a small Gujarat contract manufacturer compounding fast. Then the cash flow statement arrives and files a dissent: operating activities consumed ₹14.62 crore during the same year the P&L reported record profit.

The gap between the two documents is the whole story. Profit is an opinion formed on the income statement; cash is a fact settled at the bank. For FY26 the two disagree by roughly ₹24 crore.

There is more in the record. A SEBI adjudication order dated 7 January 2026 imposed a ₹1,00,000 penalty over disclosures made before the May 2025 IPO. Operating margin slipped from 20.72% to 16.68%. Receivables climbed to ₹22.4 crore. Promoters — four men holding 17.69% each — control 73.52%.

The company grew revenue 56% and its operating cash balance went underwater. How both are true at once is what the next fourteen sections lay out.

2. Introduction

Accretion Pharmaceuticals was incorporated in 2012 and manufactures pharmaceutical formulations — tablets, capsules, oral liquids, external preparations — out of a single facility in Sanand, Gujarat. It listed on the NSE Emerge SME platform on 21 May 2025, raising ₹29.75 crore via a fresh issue of 29,46,000 shares at ₹101 each.

The business is contract-and-third-party manufacturing for domestic and export markets, serving private institutions, government buyers, and other pharmaceutical companies. Management frames the identity plainly on its earnings call: a CDMO manufacturer, not a front-end brand.

FY26 is the first full year with a listed-company paper trail, and it is a busy one. The IPO closed in the year. Independent directors were appointed at the September 2025 AGM. A SEBI show-cause notice landed in October 2025 and became a ₹1,00,000 penalty order in January 2026. The audited FY26 results were approved by the board on 8 May 2026 with an unmodified auditor opinion from VSSB & Associates.

For a company that only recently acquired an investor-relations department, a fair amount has already happened to it.

3. Business Model: WTF Do They Even Do?

They make other people’s medicines. That is the honest one-line version, and management does not pretend otherwise — on the November 2025 call, Vivek Patel described the company as a CDMO that manufactures “according to demand,” not a brand owner chasing shelf space.

The product mix spans antibiotics, anti-inflammatories, gastro, dermatology, and nutraceuticals across tablets, capsules, oral liquids, and external preparations. Per the DRHP, tablets contributed 41.5% of revenue, oral liquids 28.5%, capsules 15%. The single Sanand plant carried a stated formulation capacity of 1.03 billion units annually.

The export model is the interesting part. Rather than build in-country sales teams, management says it ships directly to importers and distributors — “the bigger player… traditionally working as their supply chain only,” per the CFO. Roughly 70% of revenue is export, 30% domestic, and management clarified the domestic slice is also contract manufacturing, not owned branding. So it is a company that manufactures without marketing, in over 30 countries, under nobody’s name including its own.

Asked which therapy it specialises in, management said none — breadth is the pitch. That is a defensible strategy and also a polite way of saying the moat is the factory. A CDMO’s advantage is capacity, compliance certificates, and working capital to fund the order cycle. Two of those three, as the balance sheet will show, are expensive.

Does a broader product mix protect a contract manufacturer, or just spread the same thin margin across more SKUs?

4. Financials Overview

Figures are consolidated, in ₹ crore. The company reports on a half-yearly basis; the table below compares the March 2026 half against the year-ago half and the immediately preceding one.

Revenue in the half grew 18.2% year-on-year while operating profit rose only 4.5% — the margin did the shrinking. Note the EPS line: net profit rose from ₹4.33 crore to ₹4.92 crore, yet EPS fell from ₹5.30 to ₹4.43. That is not a profit decline. The IPO in May 2025 added shares to the denominator; more owners now split a bigger pie into smaller slices. The share count moved, not the business.

From the concall (Nov 2025): management attributed H1 FY26’s revenue jump to post-IPO capacity, a